Skip to main content

Table 3 SA-2: patient characteristics of the subgroup with clinical response recorded

From: Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study

 

Patient characteristics before PSW

Patient characteristics (%) after PSWa

CCT (n = 79)

Without CCT (n = 167)

Standardized differenceb

CCT

Without CCT

Standardized differenceb

Number (%)b or mean (SD)b

Number (%)b or mean (SD)b

Age (years)

      

  ≤ 58

42 (53)

90 (54)

0.015

51

51

≈ 0

  > 58

37 (47)

77 (46)

 

49

49

 

Gender

      

 Female

4 (5)

7 (4)

0.042

5

5

≈ 0

 Male

75 (95)

160 (96)

 

95

95

 

Residency

      

 Non-north

60 (76)

119 (71)

0.107

74

74

≈ 0

 North

19 (24)

48 (29)

 

26

26

 

Comorbidity

      

 Without

69 (87)

146 (87)

0.003

88

88

≈ 0

 Withc

10 (13)

21 (13)

 

12

12

 

BMI (kg/m2)

      

  ≤ 18.5

15 (19)

36 (22)

0.064

19

19

≈ 0

  > 18.5

64 (81)

131 (78)

 

81

81

 

Drinking

      

 No

11 (14)

22 (13)

0.022

14

14

≈ 0

 Yes

68 (86)

145 (87)

 

86

86

 

Smoking

      

 No

8 (10)

20 (12)

0.059

11

11

≈ 0

 Yes

71 (90)

147 (88)

 

89

89

 

Grade

      

 Poorly

25 (32)

40 (24)

0.172

31

31

≈ 0

 Well/moderately differentiated

54 (68)

127 (76)

 

69

69

 

Tumor location

      

 Upper

43 (54)

65 (39)

 

50

50

 

 Middle

25 (32)

75 (45)

0.275

35

35

≈ 0

 Lower

11 (14)

27 (16)

0.063

15

15

≈ 0

Tumor size (cm)

      

  ≤ 5 cm

34 (43)

61 (37)

0.133

43

43

≈ 0

  > 5 cm

45 (57)

106 (63)

 

57

57

 

Clinical T-stage

      

 T1–T2

7 (9)

17 (10)

0.045

8

8

≈ 0

 T3–T4

72 (91)

150 (90)

 

92

92

 

Clinical N-stage

      

 N0

7 (9)

8 (5)

0.162

7

7

≈ 0

 N1–N2

72 (91)

159 (95)

 

93

93

 

Clinical stage

      

 II

9 (11)

14 (8)

0.101

10

10

≈ 0

 III

70 (89)

153 (92)

 

90

90

 

Reason for no surgery

      

 Without contraindication

75 (95)

154 (92)

0.111

94

94

≈ 0

 With contraindication

4 (5)

13 (8)

 

6

6

 

RT modality

      

 3DCRT

7 (9)

4 (2)

0.283

5

5

≈ 0

 IMRT

72 (91)

163 (98)

 

95

95

 

Use of PET

      

 No

34 (43)

42 (25)

0.384

35

35

≈ 0

 Yes

45 (57)

125 (75)

 

65

65

 

RT break

      

  ≤ 1 week

63 (80)

125 (75)

0.117

79

79

≈ 0

  > 1 week

16 (20)

42 (25)

 

21

21

 

RT dose

      

 Low

19 (24)

54 (32)

0.185

26

26

≈ 0

 High

60 (76)

113 (68)

 

74

74

 

Induction chemotherapy

      

 Without

74 (94)

162 (97)

0.159

95

95

≈ 0

 With

5 (6)

5 (3)

 

5

5

 
  1. 3DCRT, three-dimensional radiotherapy; BMI, Body Mass Index; CCT, consolidative chemotherapy; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; PET, positron emission tomography; PSW, propensity score weighting; RT, radiotherapy; SD, standard deviation
  2. aWeighted proportion for each group
  3. bRounded
  4. cModified Carlson comorbidity score ≥ 1